Other Name(s):

3,5,4' TriHydroxy-Transstibene, (E)- 5-(4-hydroxystyryl)benzene-1,3-diol, 3,4',5-stilbenetriol, 3,5,4' -trihydroxystilbene, 3,4',5-trihydroxystilbene, 3,5,4'-trihydroxy-trans-stilbene, Cis-Resveratrol, Extrait de Vin, Extrait de Vin Rouge, Kojo-Kon, Phytoalexin, Phytoalexine, Phytoestrogen, Phyto-œstrogène, Pilule de Vin, Protykin, Red Wine Extract, Resvératrol, Resveratrols, Resvératrols, RSV, RSVL, Stilbene Phytoalexin, Trans-Resveratrol, Trans-Resvératrol, Wine Extract, Wine Pill.


Resveratrol is a chemical found in red wine, red grape skins, purple grape juice, mulberries, and in smaller amounts in peanuts. It is used as a medicine.

People use resveratrol for "hardening of the arteries" (atherosclerosis), lowering "bad" (LDL) cholesterol levels, increasing "good" (HDL) cholesterol levels, and preventing cancer and heart disease. It is also used for symptoms of a lung disorder "chronic obstructive pulmonary disease" and to improve the health of the liver in people with liver damage not caused by drinking alcohol. Resveratrol is used to improve glucose levels in the blood in people with diabetes, to reduce body fat in people with a condition called metabolic syndrome, and to slow signs of aging in the skin.

Some people apply resveratrol to their skin to treat acne.

Resveratrol is used as a nasal spray for symptoms of seasonal allergies (hay fever).

How does it work?

Resveratrol might expand blood vessels and reduce the activity of cells important in blood clotting. Some research suggests that resveratrol has weak estrogen (a female hormone) effects. It may also decrease pain and swelling (inflammation). Resveratrol might reduce levels of sugar (glucose) in the blood and help the body fight against disease. It might also prevent proteins in the brain from sticking together to help prevent diseases such as Alzheimer's disease.


Vitamin D Deficiency: How Much Vitamin D Is Enough? See Slideshow

Uses & Effectiveness

Possibly Effective for...

  • Diabetes. Taking 250-1000 mg of resveratrol daily for up to 3 months appears to help control blood sugar levels and improve how well insulin works in people with type 2 diabetes. Lower doses of 5 mg twice daily for 4 weeks might also improve how well insulin works. Resveratrol does not seem to affect blood sugar levels or how well insulin works in people without diabetes.

Possibly Ineffective for...

  • Heart disease. People who consume higher amounts of dietary resveratrol do not seem to have a lower risk of heart disease compared to people who consume lower amounts. Also, taking resveratrol by mouth does not seem to improve levels of cholesterol or blood fats called triglycerides in people at risk for heart disease. One early study shows that taking 10 mg of resveratrol daily for 3 months may improve how well the heart pumps blood in people with a history of heart attack and evidence of damaged heart blood vessels. However, the improvement is small, and resveratrol doesn't improve blood pressure or blood thickness in people with this condition.

Insufficient Evidence to Rate Effectiveness for...

  • Acne. Early research shows that applying a gel containing resveratrol to the face for 60 days reduces the severity of acne.
  • Seasonal allergies (hay fever). . Early research shows that using a nasal spray containing resveratrol and beta-glucan three times daily for 2 months reduces runny nose and sneezing in young children and adolescents with pollen allergy.
  • Cancer. People who consume higher amounts of dietary resveratrol do not seem to have a lower risk of cancer compared to people who consume lower amounts.
  • Lung disease (chronic obstructive pulmonary disease, COPD). Early research suggests that taking a combination product containing resveratrol, vitamin C, zinc, and flavonoids slightly reduces coughing and mucus production in people with COPD. But it's not clear if the benefit is due to resveratrol or other ingredients.
  • Metabolic syndrome. Early research suggests that taking resveratrol helps to reduce body fat in people with metabolic syndrome. However, taking resveratrol does not help to lower blood pressure or levels of cholesterol or blood sugar.
  • Fatty liver disease not related to alcohol (nonalcoholic fatty liver disease; NAFLD). One early study shows that taking 3000 mg of resveratrol daily for 8 weeks does not improve liver function or reduce fat buildup in the liver in overweight or obese men with NAFLD. However, taking 500 mg of resveratrol daily for 12 weeks while also dieting and exercising reduces fat buildup in the liver and improves liver function in people with NAFLD.
  • Aging of the skin.
  • "Hardening of the arteries" (atherosclerosis)..
  • Other conditions.
More evidence is needed to rate resveratrol for these uses.

Natural Medicines Comprehensive Database rates effectiveness based on scientific evidence according to the following scale: Effective, Likely Effective, Possibly Effective, Possibly Ineffective, Likely Ineffective, and Insufficient Evidence to Rate (detailed description of each of the ratings).

Side Effects

Resveratrol is LIKELY SAFE when used in the amounts found in foods. Resveratrol is POSSIBLY SAFE when applied to the skin for up to 30 days or when taken by mouth in doses up to 1500 mg daily for up to 3 months. Higher doses of up to 3000 mg have been taken by mouth safely for up to 8 weeks.

In children, resveratrol is POSSIBLY SAFE when sprayed in the nostrils for up to 2 months.


Next to red peppers, you can get the most vitamin C from ________________. See Answer

Special Precautions & Warnings

Pregnancy and breast-feeding: Resveratrol is LIKELY SAFE when used in amounts found in some foods. However, during pregnancy and breast-feeding, the source of resveratrol is important. Resveratrol is found in grape skins, grape juice, wine, and other food sources. Wine should not be used as a source of resveratrol during pregnancy and breast-feeding.

Bleeding disorders: Resveratrol might slow blood clotting and increase the risk of bleeding in people with bleeding disorders.

Hormone-sensitive condition such as breast cancer, uterine cancer, ovarian cancer, endometriosis, or uterine fibroids: Resveratrol might act like estrogen. If you have any condition that might be made worse by exposure to estrogen, don"t use resveratrol.

Surgery: Resveratrol might increase the risk of bleeding during and after surgery. Stop using resveratrol at least 2 weeks before a scheduled surgery.


Medications changed by the liver (Cytochrome P450 1A1 (CYP1A1) substrates)Interaction Rating: Moderate Be cautious with this combination.Talk with your health provider.

Some medications are changed and broken down by the liver. Resveratrol might decrease how quickly the liver breaks down some medications. In theory, taking resveratrol along with some medications that are broken down by the liver may increase the effects and side effects of some medications.

Some medications changed by the liver include chlorzoxazone, theophylline, and bufuralol.

Medications changed by the liver (Cytochrome P450 1A2 (CYP1A2) substrates)Interaction Rating: Moderate Be cautious with this combination.Talk with your health provider.

Some medications are changed and broken down by the liver. Resveratrol might decrease how quickly the liver breaks down some medications. In theory, taking resveratrol along with some medications that are broken down by the liver may increase the effects and side effects of some medications.

Some medications changed by the liver include clozapine (Clozaril), cyclobenzaprine (Flexeril), fluvoxamine (Luvox), haloperidol (Haldol), imipramine (Tofranil), mexiletine (Mexitil), olanzapine (Zyprexa), pentazocine (Talwin), propranolol (Inderal), tacrine (Cognex), zileuton (Zyflo), zolmitriptan (Zomig), and others.

Medications changed by the liver (Cytochrome P450 1B1 (CYP1B1) substrates)Interaction Rating: Moderate Be cautious with this combination.Talk with your health provider.

Some medications are changed and broken down by the liver. Resveratrol might decrease how quickly the liver breaks down some medications. In theory, taking resveratrol along with some medications that are broken down by the liver may increase the effects and side effects of some medications.

Some medications changed by the liver include theophylline, omeprazole, clozapine, progesterone, lansoprazole, flutamide, oxaliplatin, erlotinib, and caffeine.

Medications changed by the liver (Cytochrome P450 2C19 (CYP2C19) substrates)Interaction Rating: Moderate Be cautious with this combination.Talk with your health provider.

Some medications are changed and broken down by the liver. Resveratrol might decrease how quickly the liver breaks down some medications. In theory, taking resveratrol along with some medications that are broken down by the liver may increase the effects and side effects of some medications.

Some medications changed by the liver include amitriptyline (Elavil), carisoprodol (Soma), citalopram (Celexa), diazepam (Valium), lansoprazole (Prevacid), omeprazole (Prilosec), phenytoin (Dilantin), warfarin, and many others.

Medications changed by the liver (Cytochrome P450 2E1 (CYP2E1) substrates)Interaction Rating: Moderate Be cautious with this combination.Talk with your health provider.

Some medications are changed and broken down by the liver. Resveratrol might decrease how quickly the liver breaks down some medications. In theory, taking resveratrol along with some medications that are broken down by the liver may increase the effects and side effects of some medications.

Some medications changed by the liver include acetaminophen, chlorzoxazone (Parafon Forte), ethanol, theophylline, and anesthetics such as enflurane (Ethrane), halothane (Fluothane), isoflurane (Forane), methoxyflurane (Penthrane).

Medications changed by the liver (Cytochrome P450 3A4 (CYP3A4) substrates)Interaction Rating: Moderate Be cautious with this combination.Talk with your health provider.

Some medications are changed and broken down by the liver. Resveratrol might decrease how quickly the liver breaks down some medications. In theory, taking resveratrol along with some medications that are broken down by the liver may increase the effects and side effects of some medications. However, some early research shows conflicting results.

Some medications changed by the liver include some calcium channel blockers (diltiazem, nicardipine, verapamil), chemotherapeutic agents (etoposide, paclitaxel, vinblastine, vincristine, vindesine), antifungals (ketoconazole, itraconazole), glucocorticoids, alfentanil (Alfenta), cisapride (Propulsid), fentanyl (Sublimaze), lidocaine (Xylocaine), losartan (Cozaar), fexofenadine (Allegra), midazolam (Versed), and otherslovastatin (Mevacor), ketoconazole (Nizoral), itraconazole (Sporanox), fexofenadine (Allegra), triazolam (Halcion), and many others.

Medications that slow blood clotting (Anticoagulant / Antiplatelet drugs)Interaction Rating: Moderate Be cautious with this combination.Talk with your health provider.

Resveratrol might slow blood clotting. Taking resveratrol along with medications that also slow clotting might increase the chances of bruising and bleeding.

Some medications that slow blood clotting include aspirin, clopidogrel (Plavix), diclofenac (Voltaren, Cataflam, others), ibuprofen (Advil, Motrin, others), naproxen (Anaprox, Naprosyn, others), dalteparin (Fragmin), enoxaparin (Lovenox), heparin, warfarin (Coumadin), and others.


The following doses have been studied in scientific research:



  • For diabetes: 250-1000 mg daily for up to 3 months.

FDA Logo

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Aggarwal, B. B., Bhardwaj, A., Aggarwal, R. S., Seeram, N. P., Shishodia, S., and Takada, Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res. 2004;24(5A):2783-2840. View abstract.

Albani, D., Polito, L., and Forloni, G. Sirtuins as novel targets for Alzheimer's disease and other neurodegenerative disorders: experimental and genetic evidence. J Alzheimers.Dis 2010;19(1):11-26. View abstract.

Almeida, L., Vaz-da-Silva, M., Falcao, A., Soares, E., Costa, R., Loureiro, A. I., Fernandes-Lopes, C., Rocha, J. F., Nunes, T., Wright, L., and Soares-da-Silva, P. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol.Nutr.Food Res 2009;53 Suppl 1:S7-15. View abstract.

Bagchi, D., Bagchi, M., Stohs, S. J., Das, D. K., Ray, S. D., Kuszynski, C. A., Joshi, S. S., and Pruess, H. G. Free radicals and grape seed proanthocyanidin extract: importance in human health and disease prevention. Toxicology 8-7-2000;148(2-3):187-197. View abstract.

Bass, T. M., Weinkove, D., Houthoofd, K., Gems, D., and Partridge, L. Effects of resveratrol on lifespan in Drosophila melanogaster and Caenorhabditis elegans. Mech.Ageing Dev 2007;128(10):546-552. View abstract.

Baur, J. A. and Sinclair, D. A. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006;5(6):493-506. View abstract.

Bhat, K. P. and Pezzuto, J. M. Resveratrol exhibits cytostatic and antiestrogenic properties with human endometrial adenocarcinoma (Ishikawa) cells. Cancer Res. 8-15-2001;61(16):6137-6144. View abstract.

Bhat, K. P., Lantvit, D., Christov, K., Mehta, R. G., Moon, R. C., and Pezzuto, J. M. Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. Cancer Res. 10-15-2001;61(20):7456-7463. View abstract.

Bhatt, J. K., Thomas, S., and Nanjan, M. J. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr.Res. 2012;32(7):537-541. View abstract.

Bhavnani, B. R., Cecutti, A., Gerulath, A., Woolever, A. C., and Berco, M. Comparison of the antioxidant effects of equine estrogens, red wine components, vitamin E, and probucol on low-density lipoprotein oxidation in postmenopausal women. Menopause. 2001;8(6):408-419. View abstract.

Bost, J., Smoliga, J. M., Bost, K. M., and Maroon, J. C. Three Months Oral Supplementation of a Unique Polyphenol Mixture Improves Physical and Neurocognitive Performance Indicators in Sedentary Adults: 2205. Medicine & Science in Sports & Exercise 2008;40(5):S246.

Bournival, J., Quessy, P., and Martinoli, M. G. Protective effects of resveratrol and quercetin against MPP+ -induced oxidative stress act by modulating markers of apoptotic death in dopaminergic neurons. Cell Mol.Neurobiol. 2009;29(8):1169-1180. View abstract.

Bradamante, S., Piccinini, F., Barenghi, L., Bertelli, A. A., De Jonge, R., Beemster, P., and De Jong, J. W. Does resveratrol induce pharmacological preconditioning? Int.J Tissue React. 2000;22(1):1-4. View abstract.

Brasnyo, P., Molnar, G. A., Mohas, M., Marko, L., Laczy, B., Cseh, J., Mikolas, E., Szijarto, I. A., Merei, A., Halmai, R., Meszaros, L. G., Sumegi, B., and Wittmann, I. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr. 2011;106(3):383-389. View abstract.

Brown, V. A., Patel, K. R., Viskaduraki, M., Crowell, J. A., Perloff, M., Booth, T. D., Vasilinin, G., Sen, A., Schinas, A. M., Piccirilli, G., Brown, K., Steward, W. P., Gescher, A. J., and Brenner, D. E. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res 11-15-2010;70(22):9003-9011. View abstract.

Burkitt, M. J. and Duncan, J. Effects of trans-resveratrol on copper-dependent hydroxyl-radical formation and DNA damage: evidence for hydroxyl-radical scavenging and a novel, glutathione-sparing mechanism of action. Arch.Biochem.Biophys. 9-15-2000;381(2):253-263. View abstract.

Calabrese, V., Cornelius, C., Mancuso, C., Pennisi, G., Calafato, S., Bellia, F., Bates, T. E., Giuffrida Stella, A. M., Schapira, T., Dinkova Kostova, A. T., and Rizzarelli, E. Cellular stress response: a novel target for chemoprevention and nutritional neuroprotection in aging, neurodegenerative disorders and longevity. Neurochem.Res 2008;33(12):2444-2471. View abstract.

Cavallaro, A., Ainis, T., Bottari, C., and Fimiani, V. Effect of resveratrol on some activities of isolated and in whole blood human neutrophils. Physiol Res. 2003;52(5):555-562. View abstract.

Chan, W. K. and Delucchi, A. B. Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4. Life Sci 11-10-2000;67(25):3103-3112. View abstract.

Chang, T. K., Lee, W. B., and Ko, H. H. Trans-resveratrol modulates the catalytic activity and mRNA expression of the procarcinogen-activating human cytochrome P450 1B1. Can.J.Physiol Pharmacol. 2000;78(11):874-881. View abstract.

Chow, H. H., Garland, L. L., Hsu, C. H., Vining, D. R., Chew, W. M., Miller, J. A., Perloff, M., Crowell, J. A., and Alberts, D. S. Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev.Res (Phila) 2010;3(9):1168-1175. View abstract.

Ciolino, H. P. and Yeh, G. C. Inhibition of aryl hydrocarbon-induced cytochrome P-450 1A1 enzyme activity and CYP1A1 expression by resveratrol. Mol.Pharmacol. 1999;56(4):760-767. View abstract.

Crandall, J. P., Oram, V., Trandafirescu, G., Reid, M., Kishore, P., Hawkins, M., Cohen, H. W., and Barzilai, N. Pilot study of resveratrol in older adults with impaired glucose tolerance. J.Gerontol.A Biol.Sci.Med.Sci. 2012;67(12):1307-1312. View abstract.

Daffner, K. R. Promoting successful cognitive aging: a comprehensive review. J Alzheimers.Dis 2010;19(4):1101-1122. View abstract.

de, Santi C., Pietrabissa, A., Mosca, F., and Pacifici, G. M. Glucuronidation of resveratrol, a natural product present in grape and wine, in the human liver. Xenobiotica 2000;30(11):1047-1054. View abstract.

Delmas, D., Rebe, C., Lacour, S., Filomenko, R., Athias, A., Gambert, P., Cherkaoui-Malki, M., Jannin, B., Dubrez-Daloz, L., Latruffe, N., and Solary, E. Resveratrol-induced apoptosis is associated with Fas redistribution in the rafts and the formation of a death-inducing signaling complex in colon cancer cells. J.Biol.Chem. 10-17-2003;278(42):41482-41490. View abstract.

Dobrydneva, Y., Williams, R. L., and Blackmore, P. F. trans-Resveratrol inhibits calcium influx in thrombin-stimulated human platelets. Br.J.Pharmacol. 1999;128(1):149-157. View abstract.

Dong, W., Li, N., Gao, D., Zhen, H., Zhang, X., and Li, F. Resveratrol attenuates ischemic brain damage in the delayed phase after stroke and induces messenger RNA and protein express for angiogenic factors. J Vasc.Surg. 2008;48(3):709-714. View abstract.

Dudley, J. I., Lekli, I., Mukherjee, S., Das, M., Bertelli, A. A., and Das, D. K. Does white wine qualify for French paradox? Comparison of the cardioprotective effects of red and white wines and their constituents: resveratrol, tyrosol, and hydroxytyrosol. J Agric.Food Chem. 10-22-2008;56(20):9362-9373. View abstract.

Evers, D. L., Wang, X., Huong, S. M., Huang, D. Y., and Huang, E. S. 3,4',5-Trihydroxy-trans-stilbene (resveratrol) inhibits human cytomegalovirus replication and virus-induced cellular signaling. Antiviral Res. 2004;63(2):85-95. View abstract.

Fabbrocini, G., Staibano, S., De, Rosa G., Battimiello, V., Fardella, N., Ilardi, G., La Rotonda, M. I., Longobardi, A., Mazzella, M., Siano, M., Pastore, F., De, Vita, V, Vecchione, M. L., and Ayala, F. Resveratrol-containing gel for the treatment of acne vulgaris: a single-blind, vehicle-controlled, pilot study. Am J Clin.Dermatol 4-1-2011;12(2):133-141. View abstract.

Falchetti, R., Fuggetta, M. P., Lanzilli, G., Tricarico, M., and Ravagnan, G. Effects of resveratrol on human immune cell function. Life Sci. 11-21-2001;70(1):81-96. View abstract.

Fan, E., Zhang, L., Jiang, S., and Bai, Y. Beneficial effects of resveratrol on atherosclerosis. J Med Food 2008;11(4):610-614. View abstract.

Fujitaka, K., Otani, H., Jo, F., Jo, H., Nomura, E., Iwasaki, M., Nishikawa, M., Iwasaka, T., and Das, D. K. Modified resveratrol Longevinex improves endothelial function in adults with metabolic syndrome receiving standard treatment. Nutr.Res 2011;31(11):842-847. View abstract.

Giovannini, L., Migliori, M., Longoni, B. M., Das, D. K., Bertelli, A. A., Panichi, V., Filippi, C., and Bertelli, A. Resveratrol, a polyphenol found in wine, reduces ischemia reperfusion injury in rat kidneys. J Cardiovasc.Pharmacol. 2001;37(3):262-270. View abstract.

Gruber, J., Tang, S. Y., and Halliwell, B. Evidence for a trade-off between survival and fitness caused by resveratrol treatment of Caenorhabditis elegans. Ann N Y.Acad Sci 2007;1100:530-542. View abstract.

Grujic Milanovic, J., Mihailovic-Stanojevic, N., Miloradovic, Z., Jacevic, V., Milosavljevic, I., Milanovic, S., Ivanov, M., and Jovovic, D. J. RESVERATROL REDUCES BLOOD PRESSURE, CHANGES OF ANTIOXIDANT ENZYME ACTIVITY AND HISTOLOGICAL PARAMETERS IN EXPERIMENTAL MODEL OF MALIGNANT HYPERTENSION PP.29.171. Journal of Hypertension 2010;28

Guarnieri, R., Pappacoda, A., and Solitro, S. [A resveratrol containing compound reduces oxidative stress and ameliorates clinical symptoms in COPD subjects] Un composto a base di resveratrolo riduce lo stress ossidativo e migliora la sintomatologia clinica in soggetti con BPCO. Cochrane Central Register of Controlled Trials 2009;

Guo, J. P., Yu, S., and McGeer, P. L. Simple in vitro assays to identify amyloid-beta aggregation blockers for Alzheimer's disease therapy. J Alzheimers.Dis. 2010;19(4):1359-1370. View abstract.

Hector, K. L., Lagisz, M., and Nakagawa, S. The effect of resveratrol on longevity across species: a meta-analysis. Biol.Lett. 10-23-2012;8(5):790-793. View abstract.

Holian, O., Wahid, S., Atten, M. J., and Attar, B. M. Inhibition of gastric cancer cell proliferation by resveratrol: role of nitric oxide. Am.J.Physiol Gastrointest.Liver Physiol 2002;282(5):G809-G816. View abstract.

Howells, L. M., Berry, D. P., Elliott, P. J., Jacobson, E. W., Hoffmann, E., Hegarty, B., Brown, K., Steward, W. P., and Gescher, A. J. Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases--safety, pharmacokinetics, and pharmacodynamics. Cancer Prev.Res (Phila) 2011;4(9):1419-1425. View abstract.

Howitz, K. T., Bitterman, K. J., Cohen, H. Y., Lamming, D. W., Lavu, S., Wood, J. G., Zipkin, R. E., Chung, P., Kisielewski, A., Zhang, L. L., Scherer, B., and Sinclair, D. A. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 9-11-2003;425(6954):191-196. View abstract.

Hudson, G. M., Shelmadine, B., Cooke, M., Genovese, J., Greenwood, M., and Willoughby, D. S. Resveratrol Supplementation And Changes In Glucose, Insulin, And mRNA Expression Following Exercise In Overweight Females: 2467. Medicine & Science in Sports & Exercise 2011;43(5)

Jannin, B., Menzel, M., Berlot, J. P., Delmas, D., Lancon, A., and Latruffe, N. Transport of resveratrol, a cancer chemopreventive agent, to cellular targets: plasmatic protein binding and cell uptake. Biochem.Pharmacol. 9-15-2004;68(6):1113-1118. View abstract.

Jha, R. K., Ma, Q., Sha, H., and Palikhe, M. Protective effect of resveratrol in severe acute pancreatitis-induced brain injury. Pancreas 2009;38(8):947-953. View abstract.

Kennedy, D. O., Wightman, E. L., Reay, J. L., Lietz, G., Okello, E. J., Wilde, A., and Haskell, C. F. Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: a double-blind, placebo-controlled, crossover investigation. Am J Clin.Nutr. 2010;91(6):1590-1597. View abstract.

Kim, Y. A., Lee, W. H., Choi, T. H., Rhee, S. H., Park, K. Y., and Choi, Y. H. Involvement of p21WAF1/CIP1, pRB, Bax and NF-kappaB in induction of growth arrest and apoptosis by resveratrol in human lung carcinoma A549 cells. Int.J.Oncol. 2003;23(4):1143-1149. View abstract.

Kimura, Y., Okuda, H., and Kubo, M. Effects of stilbenes isolated from medicinal plants on arachidonate metabolism and degranulation in human polymorphonuclear leukocytes. J Ethnopharmacol. 1995;45(2):131-139. View abstract.

Kirk, R. I., Deitch, J. A., Wu, J. M., and Lerea, K. M. Resveratrol decreases early signaling events in washed platelets but has little effect on platalet in whole food. Blood Cells Mol.Dis. 2000;26(2):144-150. View abstract.

Kitada, M., Kume, S., Imaizumi, N., and Koya, D. Resveratrol improves oxidative stress and protects against diabetic nephropathy through normalization of Mn-SOD dysfunction in AMPK/SIRT1-independent pathway. Diabetes 2011;60(2):634-643. View abstract.

Klabunde, T., Petrassi, H. M., Oza, V. B., Raman, P., Kelly, J. W., and Sacchettini, J. C. Rational design of potent human transthyretin amyloid disease inhibitors. Nat Struct.Biol. 2000;7(4):312-321. View abstract.

Klinge, C. M., Risinger, K. E., Watts, M. B., Beck, V., Eder, R., and Jungbauer, A. Estrogenic activity in white and red wine extracts. J Agric.Food Chem 3-26-2003;51(7):1850-1857. View abstract.

Klink, J. C., Poulton, S., Antonelli, J., Potter, M. Q., Jayachandran, J., Tewari, A. K., Febbo, P. G., Pizzo, S. V., and Freedland, S. RESVERATROL ALTERS PROSTATE CANCER XENOGRAFT GROWTH: 724. Journal of Urology 2009;181(4)

Knight, C. M., Gutierrez-Juarez, R., Lam, T. K., Arrieta-Cruz, I., Huang, L., Schwartz, G., Barzilai, N., and Rossetti, L. Mediobasal hypothalamic SIRT1 is essential for resveratrol's effects on insulin action in rats. Diabetes 2011;60(11):2691-2700. View abstract.

Knobloch, J., Sibbing, B., Jungck, D., Lin, Y., Urban, K., Stoelben, E., Strauch, J., and Koch, A. Resveratrol impairs the release of steroid-resistant inflammatory cytokines from human airway smooth muscle cells in chronic obstructive pulmonary disease. J Pharmacol.Exp.Ther 2010;335(3):788-798. View abstract.

la, Porte C., Voduc, N., Zhang, G., Seguin, I., Tardiff, D., Singhal, N., and Cameron, D. W. Steady-State pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects. Clin.Pharmacokinet. 2010;49(7):449-454. View abstract.

Le Couteur, D. G. and Sinclair, D. A. A blueprint for developing therapeutic approaches that increase healthspan and delay death. J Gerontol.A Biol.Sci.Med Sci. 2010;65(7):693-694. View abstract.

Lee, J. E. and Safe, S. Involvement of a post-transcriptional mechanism in the inhibition of CYP1A1 expression by resveratrol in breast cancer cells. Biochem.Pharmacol. 10-15-2001;62(8):1113-1124. View abstract.

Levenson, A. S., Gehm, B. D., Pearce, S. T., Horiguchi, J., Simons, L. A., Ward, J. E., III, Jameson, J. L., and Jordan, V. C. Resveratrol acts as an estrogen receptor (ER) agonist in breast cancer cells stably transfected with ER alpha. Int.J.Cancer 5-1-2003;104(5):587-596. View abstract.

Liang, Y. C., Tsai, S. H., Chen, L., Lin-Shiau, S. Y., and Lin, J. K. Resveratrol-induced G2 arrest through the inhibition of CDK7 and p34CDC2 kinases in colon carcinoma HT29 cells. Biochem.Pharmacol. 4-1-2003;65(7):1053-1060. View abstract.

Lin, J. K. and Tsai, S. H. Chemoprevention of cancer and cardiovascular disease by resveratrol. Proc.Natl.Sci.Counc.Repub.China B 1999;23(3):99-106. View abstract.

Ma, Z. H. and Ma, Q. Y. Resveratrol: a medical drug for acute pancreatitis. World J Gastroenterol. 6-7-2005;11(21):3171-3174. View abstract.

Martinez, J. and Moreno, J. J. Effect of resveratrol, a natural polyphenolic compound, on reactive oxygen species and prostaglandin production. Biochem.Pharmacol 4-1-2000;59(7):865-870. View abstract.

Molnar, V. and Garai, J. Plant-derived anti-inflammatory compounds affect MIF tautomerase activity. Int.Immunopharmacol. 2005;5(5):849-856. View abstract.

Naderali, E. K., Doyle, P. J., and Williams, G. Resveratrol induces vasorelaxation of mesenteric and uterine arteries from female guinea-pigs. Clin Sci (Lond) 2000;98(5):537-543. View abstract.

Nicolini, G., Rigolio, R., Miloso, M., Bertelli, A. A., and Tredici, G. Anti-apoptotic effect of trans-resveratrol on paclitaxel-induced apoptosis in the human neuroblastoma SH-SY5Y cell line. Neurosci.Lett. 4-13-2001;302(1):41-44. View abstract.

Olas, B., Wachowicz, B., Bald, E., and Glowacki, R. The protective effects of resveratrol against changes in blood platelet thiols induced by platinum compounds. J.Physiol Pharmacol. 2004;55(2):467-476. View abstract.

Olas, B., Wachowicz, B., Saluk-Juszczak, J., and Zielinski, T. Effect of resveratrol, a natural polyphenolic compound, on platelet activation induced by endotoxin or thrombin. Thromb.Res 8-15-2002;107(3-4):141-145. View abstract.

Orallo, F. Trans-resveratrol: a magical elixir of eternal youth? Curr.Med Chem. 2008;15(19):1887-1898. View abstract.

Patel, K. R., Brown, V. A., Jones, D. J., Britton, R. G., Hemingway, D., Miller, A. S., West, K. P., Booth, T. D., Perloff, M., Crowell, J. A., Brenner, D. E., Steward, W. P., Gescher, A. J., and Brown, K. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res 10-1-2010;70(19):7392-7399. View abstract.

Pearson, K. J., Baur, J. A., Lewis, K. N., Peshkin, L., Price, N. L., Labinskyy, N., Swindell, W. R., Kamara, D., Minor, R. K., Perez, E., Jamieson, H. A., Zhang, Y., Dunn, S. R., Sharma, K., Pleshko, N., Woollett, L. A., Csiszar, A., Ikeno, Y., Le Couteur, D., Elliott, P. J., Becker, K. G., Navas, P., Ingram, D. K., Wolf, N. S., Ungvari, Z., Sinclair, D. A., and de Cabo, R. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab 2008;8(2):157-168. View abstract.

Pendurthi, U. R., Williams, J. T., and Rao, L. V. Resveratrol, a polyphenolic compound found in wine, inhibits tissue factor expression in vascular cells : A possible mechanism for the cardiovascular benefits associated with moderate consumption of wine. Arterioscler.Thromb.Vasc.Biol 1999;19(2):419-426. View abstract.

Piver, B., Berthou, F., Dreano, Y., and Lucas, D. Differential inhibition of human cytochrome P450 enzymes by epsilon-viniferin, the dimer of resveratrol: comparison with resveratrol and polyphenols from alcoholized beverages. Life Sci. 7-18-2003;73(9):1199-1213. View abstract.

Piver, B., Fer, M., Vitrac, X., Merillon, J. M., Dreano, Y., Berthou, F., and Lucas, D. Involvement of cytochrome P450 1A2 in the biotransformation of trans-resveratrol in human liver microsomes. Biochem.Pharmacol. 8-15-2004;68(4):773-782. View abstract.

Potter, G. A., Patterson, L. H., Wanogho, E., Perry, P. J., Butler, P. C., Ijaz, T., Ruparelia, K. C., Lamb, J. H., Farmer, P. B., Stanley, L. A., and Burke, M. D. The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1. Br.J.Cancer 3-4-2002;86(5):774-778. View abstract.

Pregliasco, F. and Cogo, R. [Antioxidant and immunomodulating compounds in older people undergoing seasonal influenza vaccination improve serological response and reduce tract respiratory episodes] L'uso di sostanze antiossidanti ed immunomodulanti in una popolazione anziana so. Cochrane Central Register of Controlled Trials 2010;

Provinciali, M., Re, F., Donnini, A., Orlando, F., Bartozzi, B., Di Stasio, G., and Smorlesi, A. Effect of resveratrol on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Int.J Cancer 5-20-2005;115(1):36-45. View abstract.

Rahman, I. Antioxidant therapeutic advances in COPD. Ther.Adv.Respir.Dis. 2008;2(6):351-374. View abstract.

Rakici, O., Kiziltepe, U., Coskun, B., Aslamaci, S., and Akar, F. Effects of resveratrol on vascular tone and endothelial function of human saphenous vein and internal mammary artery. Int.J Cardiol 11-2-2005;105(2):209-215. View abstract.

Rocha-Gonzalez, H. I., Ambriz-Tututi, M., and Granados-Soto, V. Resveratrol: a natural compound with pharmacological potential in neurodegenerative diseases. CNS.Neurosci.Ther 2008;14(3):234-247. View abstract.

Roehr, B. Cardiovascular researcher fabricated data in studies of red wine. BMJ 2012;344:e406. View abstract.

Rosa, F. T., Zulet, M. A., Marchini, J. S., and Martinez, J. A. Bioactive compounds with effects on inflammation markers in humans. Int J Food Sci Nutr 2012;63(6):749-765. View abstract.

Rotondo, S., Rajtar, G., Manarini, S., Celardo, A., Rotillo, D., de Gaetano, G., Evangelista, V., and Cerletti, C. Effect of trans-resveratrol, a natural polyphenolic compound, on human polymorphonuclear leukocyte function. Br.J.Pharmacol. 1998;123(8):1691-1699. View abstract.

Seely, K. A. Cannabinoid receptor inverse agonists as novel therapeutic agents." The Sciences and Engineering. The Sciences and Engineering 2009;70(4-B)

Sharma, M. and Gupta, Y. K. Chronic treatment with trans resveratrol prevents intracerebroventricular streptozotocin induced cognitive impairment and oxidative stress in rats. Life Sci 10-11-2002;71(21):2489-2498. View abstract.

Shindler, K. S., Ventura, E., Dutt, M., Elliott, P., Fitzgerald, D. C., and Rostami, A. Oral resveratrol reduces neuronal damage in a model of multiple sclerosis. J Neuroophthalmol. 2010;30(4):328-339. View abstract.

Steigerwald, M. D., Fisk, M. Z., Smoliga, J. M., and Rundell, K. W. Effects Of Resveratrol On Oxidative Stress And Vascular Function Following Exercise In Simulated Air Pollution: 2645. Medicine & Science in Sports & Exercise 2011;43(5)

Subbaramaiah, K., Michaluart, P., Chung, W. J., Tanabe, T., Telang, N., and Dannenberg, A. J. Resveratrol inhibits cyclooxygenase-2 transcription in human mammary epithelial cells. Ann.N.Y.Acad.Sci. 1999;889:214-223. View abstract.

Timmers, S., Konings, E., Bilet, L., Houtkooper, R. H., van de Weijer, T., Goossens, G. H., Hoeks, J., van der Krieken, S., Ryu, D., Kersten, S., Moonen-Kornips, E., Hesselink, M. K., Kunz, I., Schrauwen-Hinderling, V. B., Blaak, E. E., Auwerx, J., and Schrauwen, P. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 11-2-2011;14(5):612-622. View abstract.

Tome-Carneiro, J., Gonzalvez, M., Larrosa, M., Garcia-Almagro, F. J., Aviles-Plaza, F., Parra, S., Yanez-Gascon, M. J., Ruiz-Ros, J. A., Garcia-Conesa, M. T., Tomas-Barberan, F. A., and Espin, J. C. Consumption of a grape extract supplement containing resveratrol decreases oxidized LDL and ApoB in patients undergoing primary prevention of cardiovascular disease: a triple-blind, 6-month follow-up, placebo-controlled, randomized trial. Mol.Nutr Food Res 2012;56(5):810-821. View abstract.

Tome-Carneiro, J., Gonzalvez, M., Larrosa, M., Yanez-Gascon, M. J., Garcia-Almagro, F. J., Ruiz-Ros, J. A., Garcia-Conesa, M. T., Tomas-Barberan, F. A., and Espin, J. C. One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease. Am J Cardiol. 8-1-2012;110(3):356-363. View abstract.

Valenzano, D. R., Terzibasi, E., Genade, T., Cattaneo, A., Domenici, L., and Cellerino, A. Resveratrol prolongs lifespan and retards the onset of age-related markers in a short-lived vertebrate. Curr Biol 2-7-2006;16(3):296-300. View abstract.

Vaz-da-Silva, M., Loureiro, A. I., Falcao, A., Nunes, T., Rocha, J. F., Fernandes-Lopes, C., Soares, E., Wright, L., Almeida, L., and Soares-da-Silva, P. Effect of food on the pharmacokinetic profile of trans-resveratrol. Int.J Clin.Pharmacol.Ther 2008;46(11):564-570. View abstract.

Vingtdeux, V., Dreses-Werringloer, U., Zhao, H., Davies, P., and Marambaud, P. Therapeutic potential of resveratrol in Alzheimer's disease. BMC.Neurosci. 2008;9 Suppl 2:S6. View abstract.

Vitrac, X., Desmouliere, A., Brouillaud, B., Krisa, S., Deffieux, G., Barthe, N., Rosenbaum, J., and Merillon, J. M. Distribution of [14C]-trans-resveratrol, a cancer chemopreventive polyphenol, in mouse tissues after oral administration. Life Sci 4-4-2003;72(20):2219-2233. View abstract.

Walle, T., Hsieh, F., DeLegge, M. H., Oatis, J. E., Jr., and Walle, U. K. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos. 2004;32(12):1377-1382. View abstract.

Wallerath, T., Deckert, G., Ternes, T., Anderson, H., Li, H., Witte, K., and Forstermann, U. Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation 9-24-2002;106(13):1652-1658. View abstract.

Wang, M. J., Huang, H. M., Hsieh, S. J., Jeng, K. C., and Kuo, J. S. Resveratrol inhibits interleukin-6 production in cortical mixed glial cells under hypoxia/hypoglycemia followed by reoxygenation. J Neuroimmunol. 1-1-2001;112(1-2):28-34. View abstract.

Wong, R. H., Howe, P. R., Buckley, J. D., Coates, A. M., Kunz, I., and Berry, N. M. Acute resveratrol supplementation improves flow-mediated dilatation in overweight/obese individuals with mildly elevated blood pressure. Nutr.Metab Cardiovasc.Dis 2011;21(11):851-856. View abstract.

Wood, J. G., Rogina, B., Lavu, S., Howitz, K., Helfand, S. L., Tatar, M., and Sinclair, D. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 8-5-2004;430(7000):686-689. View abstract.

Wuertz, K., Quero, L., Sekiguchi, M., Klawitter, M., Nerlich, A., Konno, S., Kikuchi, S., and Boos, N. The red wine polyphenol resveratrol shows promising potential for the treatment of nucleus pulposus-mediated pain in vitro and in vivo. Spine (Phila Pa 1976.) 10-1-2011;36(21):E1373-E1384. View abstract.

Xuzhu, G., Komai-Koma, M., Leung, B. P., Howe, H. S., McSharry, C., McInnes, I. B., and Xu, D. Resveratrol modulates murine collagen-induced arthritis by inhibiting Th17 and B-cell function. Ann.Rheum.Dis 2012;71(1):129-135. View abstract.

Yoon, S. J., Cho, K. S., Lee, Y. H., Kim, D. S., and Hong, S. J. RESVERATROL INHIBITS CXCR4 MEDIATED TUMOR GROWTH AND MIGRATION OF HUMAN KIDNEY CANCER CELL IN VITRO AND IN VIVO: 428. Journal of Urology 2009;181(4):153-154.

Yu, C., Shin, Y. G., Kosmeder, J. W., Pezzuto, J. M., and van Breemen, R. B. Liquid chromatography/tandem mass spectrometric determination of inhibition of human cytochrome P450 isozymes by resveratrol and resveratrol-3-sulfate. Rapid Commun.Mass Spectrom. 2003;17(4):307-313. View abstract.

Yu, H. P., Hsu, J. C., Hwang, T. L., Yen, C. H., and Lau, Y. T. Resveratrol attenuates hepatic injury after trauma-hemorrhage via estrogen receptor-related pathway. Shock 2008;30(3):324-328. View abstract.

Yu, H. P., Hwang, T. L., Hwang, T. L., Yen, C. H., and Lau, Y. T. Resveratrol prevents endothelial dysfunction and aortic superoxide production after trauma hemorrhage through estrogen receptor-dependent hemeoxygenase-1 pathway. Crit Care Med 2010;38(4):1147-1154. View abstract.

Zbikowska, H. M. and Olas, B. Antioxidants with carcinostatic activity (resveratrol, vitamin E and selenium) in modulation of blood platelet adhesion. J Physiol Pharmacol. 2000;51(3):513-520. View abstract.

Zern, T. L., Wood, R. J., Greene, C., West, K. L., Liu, Y., Aggarwal, D., Shachter, N. S., and Fernandez, M. L. Grape polyphenols exert a cardioprotective effect in pre- and postmenopausal women by lowering plasma lipids and reducing oxidative stress. J Nutr. 2005;135(8):1911-1917. View abstract.

Zhang, H., Zhang, J., Ungvari, Z., and Zhang, C. Resveratrol improves endothelial function: role of TNF{alpha} and vascular oxidative stress. Arterioscler.Thromb.Vasc.Biol. 2009;29(8):1164-1171. View abstract.

Zou, J. G., Huang, Y. Z., Chen, Q., Wei, E. H., Hsieh, T. C., and Wu, J. M. Resveratrol inhibits copper ion-induced and azo compound-initiated oxidative modification of human low density lipoprotein. Biochem.Mol.Biol.Int. 1999;47(6):1089-1096. View abstract.

Abou-Zeid LA, El-Mowafy AM. Differential recognition of resveratrol isomers by the human estrogen receptor-alpha: molecular dynamics evidence for stereoselective ligand binding. Chirality 2004;16:190-5. View abstract.

Agri Res Svc: Dr. Duke's phytochemical and ethnobotanical databases. (Accessed 3 November 1999).

Ahmad KA, Clement MV, Hanif IM, Pervaiz S. Resveratrol inhibits drug-induced apoptosis in human leukemia cells by creating an intracellular milieu nonpermissive for death execution. Cancer Res 2004;64:1452-9. View abstract.

Basly, J. P., Marre-Fournier, F., Le Bail, J. C., Habrioux, G., and Chulia, A. J. Estrogenic/antiestrogenic and scavenging properties of (E)- and (Z)-resveratrol. Life Sci. 1-21-2000;66(9):769-777. View abstract.

Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006;444:337-42. View abstract.

Bertelli A, Bertelli AA, Gozzini A, Giovannini L. Plasma and tissue resveratrol concentrations and pharmacological activity. Drugs Exp Clin Res 1998;24:133-8. View abstract.

Bertelli AA, Giovannini L, Bernini W, et al. Antiplatelet activity of cis-resveratrol. Drugs Exp Clin Res 1996;22:61-3. View abstract.

Bertelli AA, Giovannini L, Giannessi D, et al. Antiplatelet activity of synthetic and natural resveratrol in red wine. Int J Tissue React 1995;17:1-3. View abstract.

Boocock DJ, Faust GE, Patel KR, et al. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 2007;16:1246-52. View abstract.

Bowers JL, Tyulmenkov VV, Jernigan SC, Klinge CM. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology 2000;141:3657-67.

Bujanda L, Garcia-Barcina M, Gutierrez-de Juan V, et al. Effect of resveratrol on alcohol-induced mortality and liver lesions in mice. BMC Gastroenterol 2006;6:35. View abstract.

Carbo N, Costelli P, Baccino FM, et al. Resveratrol, a natural product present in wine, decreases tumour growth in a rat tumour model. Biochem Biophys Res Commun 1999;254:739-43. View abstract.

Chachay VS, Macdonald GA, Martin JH, Whitehead JP, O'Moore-Sullivan TM, Lee P, Franklin M, Klein K, Taylor PJ, Ferguson M, Coombes JS, Thomas GP, Cowin GJ, Kirkpatrick CM, Prins JB, Hickman IJ. Resveratrol does not benefit patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014 Dec;12(12):2092-103.e1-6. View abstract.

Chang, T. K., Chen, J., and Lee, W. B. Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2. J.Pharmacol.Exp.Ther. 2001;299(3):874-882. View abstract.

Chen CK, Pace-Asciak CR. Vasorelaxing activity of resveratrol and quercetin in isolated rat aorta. Gen Pharmacol 1996;27:363-6. View abstract.

Creasy LL, Coffee M. Phytoalexin production potential of grape berries. J Am Soc Hortic Sci. 1988;113:230-234.

Crowell JA, Korytko PJ, Morrissey RL, Booth TD, Levine BS. Resveratrol-associated renal toxicity. Toxicol Sci. 2004 Dec;82(2):614-9. View abstract.

Culpitt SV, Rogers DF, Fenwick PS, et al. Inhibition by red wine extract, resveratrol, of cytokine release by alveolar macrophages in COPD. Thorax 2003;58:942-6. View abstract.

Davy BM, Melby CL, Beske SD, et al. Oat consumption does not affect resting casual and ambulatory 24-h arterial blood pressure in men with high-normal blood pressure to stage I hypertension. J Nutr 2002;132:394-8.. View abstract.

Docherty JJ, Fu MM, Stiffler BS, et al. Resveratrol inhibition of herpes simplex virus replication. Antiviral Res 1999;43:145-55. View abstract.

Elmali N, Baysal O, Harma A, et al. Effects of resveratrol in inflammatory arthritis. Inflammation 2007;30:1-6. View abstract.

Faghihzadeh F, Adibi P, Rafiei R, Hekmatdoost A. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. Nutr Res. 2014 Oct;34(10):837-43. View abstract.

Gao X, Deeb D, Media J, et al. Immunomodulatory activity of resveratrol: discrepant in vitro and in vivo immunological effects. Biochem Pharmacol 2003;66:2427-35. View abstract.

Gehm BD, McAndrews JM, Chien PY, Jameson JL. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci U S A 1997;94:14138-43. View abstract.

Goldberg DM, Yan J, Soleas GJ. Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin Biochem 2003;36:79-87.. View abstract.

Hascalik S, Celik O, Turkoz Y, et al. Resveratrol, a red wine constituent polyphenol, protects from ischemia-reperfusion damage of the ovaries. Gynecol Obstet Invest 2004;57:218-23. View abstract.

Holmes-McNary M, Baldwin AS, Jr. Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IkappaB kinase. Cancer Res 2000;60:3477-83. View abstract.

Huang C, Ma WY, Goranson A, Dong Z. Resveratrol suppresses cell transformation and induces apoptosis through a p53-dependent pathway. Carcinogenesis 1999;20:237-42. View abstract.

Hwang D, Fischer NH, Jang BC, et al. Inhibition of the expression of inducible cyclooxygenase and proinflammatory cytokines by sesquiterpene lactones in macrophages correlates with the inhibition of MAP kinases. Biochem Biophys Res Commun 1996;226:810-8.. View abstract.

Jacobson JS, Troxel AB, Evans J, et al. Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. J Clin Oncol 2001;19:2739-45. View abstract.

Jang M, Cai L, Udeani GO, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997;275:218-20. View abstract.

Kim YA, Choi BT, Lee YT, et al. Resveratrol inhibits cell proliferation and induces apoptosis of human breast carcinoma MCF-7 cells. Oncol Rep 2004;11:441-6. View abstract.

Kozuki Y, Miura Y, Yagasaki K. Resveratrol suppresses hepatoma cell invasion independently of its anti-proliferative action.Cancer Lett 2001;167:151-6. View abstract.

Laden BP, Porter TD. Resveratrol inhibits human squalene monooxygenase. Nutr Res 2001;21:747-53.

Langcake P, McCarthy W. The relationship of resveratrol production to infection of grapevine leaves by Botrytis cinerea. Vitis. 1979;18:244-253.

Li W, Seifert M, Xu Y, Hock B. Comparative study of estrogenic potencies of estradiol, tamoxifen, bisphenol-A and resveratrol with two in vitro bioassays. Environ Int 2004;30:329-35. View abstract.

Liu K, Zhou R, Wang B, Mi MT. Effect of resveratrol on glucose control and insulin sensitivity: a meta-analysis of 11 randomized controlled trials. Am J Clin Nutr. 2014 Jun;99(6):1510-9. View abstract.

Lyons MM, Yu C, Toma RB, et al. Resveratrol in raw and baked blueberries and bilberries. J Agric Food Chem 2003;51:5867-70. View abstract.

Magyar K, Halmosi R, Palfi A, Feher G, Czopf L, Fulop A, Battyany I, Sumegi B, Toth K, Szabados E. Cardioprotection by resveratrol: A human clinical trial in patients with stable coronary artery disease. Clin Hemorheol Microcirc. 2012;50(3):179-87. View abstract.

Martin AR, Villegas I, La Casa C, de la Lastra CA. Resveratrol, a polyphenol found in grapes, suppresses oxidative damage and stimulates apoptosis during early colonic inflammation in rats. Biochem Pharmacol 2004;67:1399-410. View abstract.

Mastromarino P, Capobianco D, Cannata F, Nardis C, Mattia E, De Leo A, Restignoli R, Francioso A, Mosca L. Resveratrol inhibits rhinovirus replication and expression of inflammatory mediators in nasal epithelia. Antiviral Res. 2015 Nov;123:15-21. View abstract.

Méndez-del Villar M, González-Ortiz M, Martínez-Abundis E, Pérez-Rubio KG, Lizárraga-Valdez R. Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Metab Syndr Relat Disord. 2014 Dec;12(10):497-501. View abstract.

Meng X, Maliakal P, Lu H, et al. Urinary and plasma levels of resveratrol and quercetin in humans, mice, and rats after ingestion of pure compounds and grape juice. J Agric Food Chem 2004;52:935-42. View abstract.

Miraglia Del Giudice M, Maiello N, Capristo C, Alterio E, Capasso M, Perrone L, Ciprandi G. Resveratrol plus carboxymethyl-ß-glucan reduces nasal symptoms in children with pollen-induced allergic rhinitis. Curr Med Res Opin. 2014 Oct;30(10):1931-5. View abstract.

Mokni M, Limam F, Elkahoui S, et al. Strong cardioprotective effect of resveratrol, a red wine polyphenol, on isolated rat hearts after ischemia/reperfusion injury. Arch Biochem Biophys 2007;457:1-6. View abstract.

Mueller SO, Simon S, Chae K, et al. Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor alpha (ERalpha) and ERbeta in human cells. Toxicol Sci 2004;80:14-25. View abstract.

Murias M, Handler N, Erker T, et al. Resveratrol analogues as selective cyclooxygenase-2 inhibitors: synthesis and structure-activity relationship. Bioorg Med Chem 2004;12:5571-8. View abstract.

Opipari AW Jr, Tan L, Boitano AE, et al. Resveratrol-induced autophagocytosis in ovarian cancer cells. Cancer Res 2004;64:696-703. View abstract.

Pace-Asciak CR, Hahn S, Diamandis EP, et al. The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin Chim Acta 1995;235:207-19. View abstract.

Pace-Asciak CR, Rounova O, Hahn SE, et al. Wines and grape juices as modulators of platelet aggregation in healthy human subjects. Clin Chim Acta 1996;246:163-82. View abstract.

Palamara AT, Nencioni L, Aquilano K, De Chiara G, Hernandez L, Cozzolino F, Ciriolo MR, Garaci E. Inhibition of influenza A virus replication by resveratrol. J Infect Dis. 2005 May 15;191(10):1719-29. View abstract.

Pervaiz S. Resveratrol: from grapevines to mammalian biology. FASEB J 2003;17:1975-85. View abstract.

Piver B, Berthou F, Dreano Y, Lucas D. Inhibition of CYP3A, CYP1A and CYP2E1 activities by resveratrol and other non volatile red wine components. Toxicol Lett 2001;125:83-91. View abstract.

Price NL, Gomes AP, Ling AJ, Duarte FV, Martin-Montalvo A, North BJ, Agarwal B, Ye L, Ramadori G, Teodoro JS, Hubbard BP, Varela AT, Davis JG, Varamini B, Hafner A, Moaddel R, Rolo AP, Coppari R, Palmeira CM, de Cabo R, Baur JA, Sinclair DA. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab. 2012 May 2;15(5):675-90. View abstract.

Sahebkar A. Effects of resveratrol supplementation on plasma lipids: a systematic review and meta-analysis of randomized controlled trials. Nutr Rev. 2013 Dec;71(12):822-35. View abstract.

Savaskan E, Olivieri G, Meier F, et al. Red wine ingredient resveratrol protects from beta-amyloid neurotoxicity. Gerontology 2003;49:380-3. View abstract.

Scarlatti F, Sala G, Somenzi G, et al. Resveratrol induces growth inhibition and apoptosis in metastatic breast cancer cells via de novo ceramide signaling. FASEB J 2003;17:2339-41. View abstract.

Schneider Y, Vincent F, Duranton B, et al. Anti-proliferative effect of resveratrol, a natural component of grapes and wine, on human colonic cancer cells. Cancer Lett 2000;158:85-91.

Schriever C, Pendland SL, Mahady GB. Red wine, resveratrol, Chlamydia pneumoniae and the French connection. Atherosclerosis 2003;171:379-80. View abstract.

Semba RD, Ferrucci L, Bartali B, Urpí-Sarda M, Zamora-Ros R, Sun K, Cherubini A, Bandinelli S, Andres-Lacueva C. Resveratrol levels and all-cause mortality in older community-dwelling adults. JAMA Intern Med. 2014 Jul;174(7):1077-84. View abstract.

Shishodia S, Aggarwal BB. Resveratrol: a polyphenol for all seasons. Resveratrol in health and disease. Boca Raton, FL: CRC Press, 2005.

Soleas GJ, Diamandis EP, Goldberg DM. Resveratrol: a molecule whose time has come? And gone? Clin Biochem 1997;30:91-113. View abstract.

Szewczuk LM, Forti L, Stivala LA, Penning TM. Resveratrol is a peroxidase mediated inactivator of COX-1 but not COX-2: A mechanistic approach to the design of COX-1 selective agents. J Biol Chem 2004;279:22727-37. View abstract.

Takada Y, Bhardwaj A, Potdar P, Aggarwal BB. Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene 2004;23:9247-58. View abstract.

Trincheri NF, Nicotra G, Follo C, et al. Resveratrol induces cell death in colorectal cancer cells by a novel pathway involving lysosomal cathepsin D. Carcinogenesis 2007;28:922-31. View abstract.

Wang Q, Li H, Wang XW, et al. Resveratrol promotes differentiation and induces Fas-independent apoptosis of human medulloblastoma cells. Neurosci Lett 2003;351:83-6. View abstract.

Wang S, Moustaid-Moussa N, Chen L, Mo H, Shastri A, Su R, Bapat P, Kwun I, Shen CL. Novel insights of dietary polyphenols and obesity. J Nutr Biochem. 2014 Jan;25(1):1-18. View abstract.

Wang Z, Huang Y, Zou J, et al. Effects of red wine and wine polyphenol resveratrol on platelet aggregation in vivo and in vitro. Int J Mol Med 2002;9:77-9. View abstract.

Zhang Y, Jayaprakasam B, Seeram NP, et al. Insulin secretion and cyclooxygenase enzyme inhibition by cabernet sauvignon grape skin compounds. J Agric Food Chem 2004;52:228-33. View abstract.

Ziegler CC, Rainwater L, Whelan J, McEntee MF. Dietary resveratrol does not affect intestinal tumorigenesis in Apc(Min/+) mice. J Nutr 2004;134:5-10. View abstract.

Health Solutions From Our Sponsors